Genetically engineered mice have become the """"""""gold standard"""""""" for animal models in cancer. They are widely used to mimic human cancers with specific point mutations in tumor suppressor genes, as well as tissuespecific expression of mutations in somatic tissues. By combining several mutations in one animal, it is now possible to phenocopy human cancers that were difficult to reproduce previously in animal models. The Genetically Engineered Mouse Facility (GEMF) provides valuable resources to Cancer Center members. It generates transgenic and gene-targeted mice, performs embryo rederivations to generate pathogen-free mice, and provides cryopreservation services to archive animal models. The Mouse Resource Facility (MRF), as part of the GEMF, provides vectors for construct development, northern blots of adult and embryonic tissues, genomic DNA and cDNA libraries, and BAG filter sets. The MRF also has a small colony of Cre and lacZ transgenic mice essential for generating conditional deletions in mice. The GEMF thus provides unique opportunities to faculty to develop sophisticated animal models to study a variety of cancer problems. The GEMF has been extremely successful in generating and maintaining mouse models. In the last five years, the GEMF has generated animal models for more than 300 projects for MDACC investigators and has cryopreserved more than 120 mouse lines. A >1000% increase has been achieved in utilization of mouse resources through the MRF. The lead facility coordinator has developed new, more efficient methods of generating embryos for use by the facility. She is responsible for training faculty and their staff, and provides genetic and technical expertise to many investigators in many different programs. In addition to the facility coordinator, the GEMF is staffed by 7 highly-trained technicians. In the past five years, the GEMF has served 96 different users who represent 19 of the 20 sponsored programs;97% of the investigators served are MDACC faculty. To better serve the needs of our investigators and add needed capacity, a small satellite facility was added recently to the South Campus. This expansion will enable the GEMF to develop more models and offer additional services. The GEMF is currently funded from multiple sources, including 53% provided by the CCSG and 45% recovered through user fees, with the remainder provided by MDACC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-37S2
Application #
8530377
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$2,882
Indirect Cost
$1,058
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10
Dang, Nam H; Ogura, Michinori; Castaigne, Sylvie et al. (2018) Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 182:583-586
Chahoud, Jad; Sui, Dawen; Erwin, William D et al. (2018) Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24:2304-2311
Andermann, Tessa M; Peled, Jonathan U; Ho, Christine et al. (2018) The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant 24:1322-1340
Tiwary, Shweta; Morales, John E; Kwiatkowski, Sam C et al. (2018) Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a. Sci Rep 8:8267
Chen, Han; Li, Chunyan; Peng, Xinxin et al. (2018) A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173:386-399.e12
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :

Showing the most recent 10 out of 12418 publications